首页> 外文期刊>EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology >Contemporary use and outcome of percutaneous coronary interventions in patients with acute coronary syndromes: Insights from the 2010 ACSIS and ACSIS-PCI surveys
【24h】

Contemporary use and outcome of percutaneous coronary interventions in patients with acute coronary syndromes: Insights from the 2010 ACSIS and ACSIS-PCI surveys

机译:急性冠脉综合征患者经皮冠状动脉介入治疗的当代使用和结果:2010年ACSIS和ACSIS-PCI调查的见解

获取原文
获取原文并翻译 | 示例
           

摘要

Aims: In patients with acute coronary syndromes (ACS), percutaneous coronary intervention (PCI) is the mainstay of treatment based on current guidelines. In this paper we describe contemporary management and outcomes of patients with ACS treated by PCI in the national ACS Israeli survey (ACSIS) performed in March and April 2010. Methods and results: The ACSIS 2010 registry was conducted in all 25 hospitals in Israel and included "all comers" admitted with ACS. In-hospital and 30-day outcome was assessed. The registry included 2,193 patients with ACS. Coronary angiography was performed in 86.1% and PCI in 75.1% of cases. The mean age was 62.5 years, the transradial approach was used in 32% of patients and overall use of drug-eluting stents was 34%. Procedural complications were extremely low at less than 1%. The thirty-day mortality rate was 2.1% and the repeated myocardial infarction (MI) rate was 2.5%. The major adverse cardiac and cerebral events (MACCE) rate was 5.6%. Multivariable analysis identified age, chronic renal failure, and hyperglycaemia on admission as independent predictors of 30-day mortality for all subsets of ACS, and Killip class >I on admission and prior MI for patients with ST-elevation ACS only. Conclusions: When evidence-based medicine is applied in the treatment of patients with ACS, clinical outcome is favourable. Several clinical predictors identify high-risk patients who require special attention.
机译:目的:根据当前指南,在急性冠脉综合征(ACS)患者中,经皮冠状动脉介入治疗(PCI)是治疗的主要手段。在本文中,我们在2010年3月和4月进行的全国ACS以色列调查(ACSIS)中描述了PCI治疗的ACS患者的当代管理和结果。方法和结果:ACSIS 2010注册中心在以色列的所有25家医院中进行,包括ACS承认“所有来者”。评估了住院和30天的预后。该注册表包括2,193例ACS患者。 86.1%的患者行冠状动脉造影,75.1%的患者行PCI。平均年龄为62.5岁,32%的患者采用经radi动脉入路,药物洗脱支架的总体使用率为34%。程序并发症非常少,不到1%。 30天死亡率为2.1%,反复心肌梗塞(MI)率为2.5%。主要不良心脏和脑事件(MACCE)率为5.6%。多变量分析将年龄,慢性肾功能衰竭和入院时的高血糖确定为ACS所有亚型的30天死亡率的独立预测因素,而入院时Killip类别> I和仅ST抬高ACS患者的先前MI为。结论:当将循证医学应用于ACS患者时,其临床结局是有利的。几种临床预测指标可识别需要特别注意的高危患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号